Novartis wins USFDA nod for Cosentyx to treat hidradenitis suppurativa in adults Ruchika Sharma1 Nov 2023 2:00 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe...
FDA approves first new biologic treatment option for hidradenitis suppurativa patients Dr. Kamal Kant Kohli1 Nov 2023 10:45 AM ISTThe US Food and Drug Administration (FDA) has approved secukinumab as first new biologic treatment option for moderate to severe hidradenitis...
FDA approves intravenous Secukinumab for Rheumatic diseases Dr. Kamal Kant Kohli11 Oct 2023 11:45 AM ISTThe US Food and Drug Administration (FDA) has approved an intravenous formulation of Secukinumab for patients with psoriatic arthritis, ankylosing...
Novartis Cosentyx IV formulation for rheumatic diseases bags USFDA okay Ruchika Sharma10 Oct 2023 1:30 PM ISTThe IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.
Novartis Cosentyx gets European Commission nod for use in adults with hidradenitis suppurativa Ruchika Sharma1 Jun 2023 11:00 AM ISTA regulatory decision from the US Food and Drug Administration is expected later this year.
Novartis gets positive CHMP opinion for Cosentyx in adults with hidradenitis suppurativa Ruchika Sharma30 April 2023 10:00 AM ISTCosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of...
Novartis lifts full year earnings on higher prescriptions Ruchika Sharma25 April 2023 11:37 AM ISTFirst-quarter group sales gained 3 percent to $12.95 billion, above an analyst consensus of $12.55 billion, driven by better than expected revenues...
Novartis to prioritise US market, unfazed by drug pricing pushback Ruchika Sharma25 Sept 2022 2:51 PM ISTNovartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
Cosentyx shows clinically meaningful symptom improvements in patients with painful skin condition in pivotal Phase III trials: Novartis Ruchika Sharma12 Sept 2022 3:00 PM ISTHidradenitis Suppurativa is a chronic, inflammatory, debilitating skin condition with systemic comorbidities that has a profoundly negative effect on...
Novartis Cosentyx gets positive CHMP opinion for expanded use in childhood arthritic conditions Ruchika Sharma23 May 2022 10:00 AM ISTBasel: Novartis has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Novartis Cosentyx gets USFDA approval Ruchika Sharma26 Dec 2021 9:45 AM ISTBasel: Novartis has announced the US Food and Drug Administration (USFDA) has approved Cosentyx (secukinumab) for the treatment of active...
Novartis pediatric psoriasis treatment Cosentyx approved in China Ruchika Sharma18 Aug 2021 3:46 PM ISTBasel: Novartis has recently announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for...
